Vermillion, Inc. (NASDAQ:VRML) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 1,096,250 shares, a decrease of 31.3% from the January 31st total of 1,596,565 shares. Approximately 3.1% of the company’s shares are short sold. Based on an average trading volume of 106,988 shares, the days-to-cover ratio is presently 10.2 days.
Vermillion (NASDAQ:VRML) opened at $1.41 on Tuesday. The company has a current ratio of 3.74, a quick ratio of 3.67 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $86.40, a PE ratio of -7.05 and a beta of 2.07. Vermillion has a 52-week low of $1.03 and a 52-week high of $2.46.
Several hedge funds have recently bought and sold shares of VRML. Essex Investment Management Co. LLC boosted its position in shares of Vermillion by 145.8% during the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock worth $390,000 after buying an additional 128,494 shares during the period. Vanguard Group Inc. boosted its position in shares of Vermillion by 0.7% during the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock worth $1,068,000 after buying an additional 4,200 shares during the period. Finally, Birchview Capital LP boosted its position in shares of Vermillion by 7.9% during the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock worth $4,433,000 after buying an additional 180,000 shares during the period. 34.64% of the stock is owned by institutional investors.
Separately, ValuEngine downgraded Vermillion from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/13/short-interest-in-vermillion-inc-vrml-declines-by-31-3.html.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.